Trupanion

The stock of Trupanion fell about 6.4% in morning trading after Piper Sandler cut its rating from "Overweight" to "Neutral" and lowered the price target from $45 to $32. Piper Sandler cited declining puppy vet visits and more costly, aging COVID cohorts as headwinds for premium growth and underwriting margins. A simultaneous downgrade by Zacks intensified the sell-off, while the new price target, near the current share price, signals only limited short-term upside. » Más en de.investing.com

Trupanion reported Q2/2026 earnings of $0.16 per share, beating the $0.1133 forecast, on revenue up 11% to $392.9m. Adjusted operating income from subscriptions rose 24% and subscription revenue grew 14% to $276.7m, while the number of insured pets increased 5% to 1.125m. The stock rose 6.7% after hours; management confirmed a 2026 revenue range of $1.584–1.601bn and adjusted operating income of $176–184m. Risks remain higher customer acquisition costs, ongoing veterinary price inflation and execution risks for new product options. » Más en de.investing.com

Trupanion shares fell to a 52-week low of $24.13 after losing about 34% over the past year and roughly 40% in recent months. For Q4 2025 the company reported earnings per share of $0.13 (forecast $0.16) and revenue of $376.9 million (+12% year over year), slightly beating expectations. Analysts cut price targets (Cantor Fitzgerald 42→34 USD, Stifel 35→31 USD) citing growth and scaling concerns, while InvestingPro signaled possible undervaluation and upside; Trupanion also announced a research collaboration with the Human Animal Bond Research Institute. » Más en de.investing.com